VLA-4 and its ligands: relevance to kidney diseases

Hamid Rabb, Raquel Rosen, German Ramirez

Research output: Contribution to journalArticle

Abstract

Alterations in cellular immunity have been implicated in many kidney diseases. The role of the adhesion molecule VLA-4 and its known ligands VCAM-1 and CS-1 have just begun to be evaluated in association with kidney diseases. VCAM-1 in human kidney is normally expressed in the Bowman's capsule, in the proximal renal tubule, and in the vascular endothelium. Up-regulation of VCAM-1 expression is seen in many different forms of glomerulonephritis as well as in a mouse model of lupus nephritis. Up-regulation of VCAM-1 expression is observed in the renal allograft with acute cellular rejection, and correlates with areas of leukocyte infiltration and vascular inflammation. CS-1 may also be up-regulated in the rejecting kidney. Animal studies on cardiac transplantation demonstrate that blockade of VLA-4 or VCAM-1 can attenuate transplant rejection. Hemodialysis patients, known to have a cellular immunodeficiency, have increased levels of soluble VCAM-1 in their serum. There is increasing evidence that there are alterations in VLA-4, VCAM-1 and CS-1 in association with kidney diseases. Further studies will be required to delineate the role of these molecules in the immunopathogenesis of select kidney diseases and the possibility of intervening in these adhesion pathways to ameliorate clinical syndromes.

Original languageEnglish (US)
Pages (from-to)417-425
Number of pages9
JournalSpringer Seminars in Immunopathology
Volume16
Issue number4
DOIs
StatePublished - Mar 1995
Externally publishedYes

Fingerprint

Integrin alpha4beta1
Vascular Cell Adhesion Molecule-1
Kidney Diseases
Ligands
Kidney
Up-Regulation
Bowman Capsule
Proximal Kidney Tubule
Lupus Nephritis
Vascular Endothelium
Graft Rejection
Heart Transplantation
Glomerulonephritis
Cellular Immunity
Allografts
Blood Vessels
Renal Dialysis
Leukocytes
Inflammation
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

VLA-4 and its ligands : relevance to kidney diseases. / Rabb, Hamid; Rosen, Raquel; Ramirez, German.

In: Springer Seminars in Immunopathology, Vol. 16, No. 4, 03.1995, p. 417-425.

Research output: Contribution to journalArticle

Rabb, Hamid ; Rosen, Raquel ; Ramirez, German. / VLA-4 and its ligands : relevance to kidney diseases. In: Springer Seminars in Immunopathology. 1995 ; Vol. 16, No. 4. pp. 417-425.
@article{10be101ab44d4d8aac370d24df55a9b3,
title = "VLA-4 and its ligands: relevance to kidney diseases",
abstract = "Alterations in cellular immunity have been implicated in many kidney diseases. The role of the adhesion molecule VLA-4 and its known ligands VCAM-1 and CS-1 have just begun to be evaluated in association with kidney diseases. VCAM-1 in human kidney is normally expressed in the Bowman's capsule, in the proximal renal tubule, and in the vascular endothelium. Up-regulation of VCAM-1 expression is seen in many different forms of glomerulonephritis as well as in a mouse model of lupus nephritis. Up-regulation of VCAM-1 expression is observed in the renal allograft with acute cellular rejection, and correlates with areas of leukocyte infiltration and vascular inflammation. CS-1 may also be up-regulated in the rejecting kidney. Animal studies on cardiac transplantation demonstrate that blockade of VLA-4 or VCAM-1 can attenuate transplant rejection. Hemodialysis patients, known to have a cellular immunodeficiency, have increased levels of soluble VCAM-1 in their serum. There is increasing evidence that there are alterations in VLA-4, VCAM-1 and CS-1 in association with kidney diseases. Further studies will be required to delineate the role of these molecules in the immunopathogenesis of select kidney diseases and the possibility of intervening in these adhesion pathways to ameliorate clinical syndromes.",
author = "Hamid Rabb and Raquel Rosen and German Ramirez",
year = "1995",
month = "3",
doi = "10.1007/BF00196097",
language = "English (US)",
volume = "16",
pages = "417--425",
journal = "Seminars in Immunopathology",
issn = "1863-2297",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - VLA-4 and its ligands

T2 - relevance to kidney diseases

AU - Rabb, Hamid

AU - Rosen, Raquel

AU - Ramirez, German

PY - 1995/3

Y1 - 1995/3

N2 - Alterations in cellular immunity have been implicated in many kidney diseases. The role of the adhesion molecule VLA-4 and its known ligands VCAM-1 and CS-1 have just begun to be evaluated in association with kidney diseases. VCAM-1 in human kidney is normally expressed in the Bowman's capsule, in the proximal renal tubule, and in the vascular endothelium. Up-regulation of VCAM-1 expression is seen in many different forms of glomerulonephritis as well as in a mouse model of lupus nephritis. Up-regulation of VCAM-1 expression is observed in the renal allograft with acute cellular rejection, and correlates with areas of leukocyte infiltration and vascular inflammation. CS-1 may also be up-regulated in the rejecting kidney. Animal studies on cardiac transplantation demonstrate that blockade of VLA-4 or VCAM-1 can attenuate transplant rejection. Hemodialysis patients, known to have a cellular immunodeficiency, have increased levels of soluble VCAM-1 in their serum. There is increasing evidence that there are alterations in VLA-4, VCAM-1 and CS-1 in association with kidney diseases. Further studies will be required to delineate the role of these molecules in the immunopathogenesis of select kidney diseases and the possibility of intervening in these adhesion pathways to ameliorate clinical syndromes.

AB - Alterations in cellular immunity have been implicated in many kidney diseases. The role of the adhesion molecule VLA-4 and its known ligands VCAM-1 and CS-1 have just begun to be evaluated in association with kidney diseases. VCAM-1 in human kidney is normally expressed in the Bowman's capsule, in the proximal renal tubule, and in the vascular endothelium. Up-regulation of VCAM-1 expression is seen in many different forms of glomerulonephritis as well as in a mouse model of lupus nephritis. Up-regulation of VCAM-1 expression is observed in the renal allograft with acute cellular rejection, and correlates with areas of leukocyte infiltration and vascular inflammation. CS-1 may also be up-regulated in the rejecting kidney. Animal studies on cardiac transplantation demonstrate that blockade of VLA-4 or VCAM-1 can attenuate transplant rejection. Hemodialysis patients, known to have a cellular immunodeficiency, have increased levels of soluble VCAM-1 in their serum. There is increasing evidence that there are alterations in VLA-4, VCAM-1 and CS-1 in association with kidney diseases. Further studies will be required to delineate the role of these molecules in the immunopathogenesis of select kidney diseases and the possibility of intervening in these adhesion pathways to ameliorate clinical syndromes.

UR - http://www.scopus.com/inward/record.url?scp=0028937059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028937059&partnerID=8YFLogxK

U2 - 10.1007/BF00196097

DO - 10.1007/BF00196097

M3 - Article

C2 - 7570292

AN - SCOPUS:0028937059

VL - 16

SP - 417

EP - 425

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

SN - 1863-2297

IS - 4

ER -